
The American Academy of Neurological Surgery Program



The Cloister Sea Island, Georgia 1986

ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGICAL SURGERY 1986

The Cloister Sea Island, Georgia November 5-8, 1986

1985-1986 Officers and Committees

PRESIDENT: Phanor L. Perot, Jr. PRESIDENT-ELECT: Shelley N. Chou VICE-PRESIDENT: Griffith R. Harsh, III SECRETARY: James T. Robertson TREASURER: Nicholas T. Zervas

EXECUTIVE COMMITTEE

Phanor L. Perot, Jr. Shelley N. Chou Griffith R. Harsh, III James T. Robertson Nicholas T. Zervas Thomas W. Langfitt Thoralf M. Sundt, Jr.

PROGRAM COMMITTEE

Chairman - Bennett M. Stein Martin H. Weiss John Tew, Jr.

MEMBERSHIP ADVISORY COMMITTEE

Chairman -Russel H. Patterson, Jr. Thomas W. Langfitt Phanor L. Perot, Jr. James T. Robertson Robert G. Ojemann Ellis B. Keener

ROUND ROBIN COMMITTEE

Chairman - William A. Buchheit Clark Watts S. J. Peerless R.A.R. Fraser

LIAISON TO BOARD OF DIRECTORS, AANS

William A. Buchheit

DELEGATES TO WORLD FEDERATION OF NEUROLOGICAL SOCIETIES Russel H. Patterson, Jr.

Phanor L. Perot, Jr.

SUBCOMMITTEE ON CORRESPONDING MEMBERSHIP

Chairman - W. Kemp Clark Griffith R. Harsh, III Ellis B. Keener

Representative to Council of the National Society for Medical Research John F. Mullan

Representative to the ABNS

Nicholas T. Zervas

Academy Award Committee

James I. Ausman Frederick A. Simeone George Ojemann

President of Women's Auxiliary

Ann Keener

Representative to International Committee on Neurological Implants David G. Kline

Round Robin Committee William A. Buchheit

Local Hosts Ann and Ellis Keener

11日 以下

THE AMERICAN ACADEMY OF NEUROLOGICAL SURGERY

November 5-8, 1986 The Cloister Sea Island, Georgia

.

Wednesday, November 5	Re-later Blackton Lourge
1:00 PM-5:00 PM	Registration - Plantation Lounge
6:30 PM-8:00 PM	Reception - Plantation Lounge
7:30 PM-9:00 PM	Dining - The Cloister (Coat and Tie Dress)
Thursday, November 6	
7:00 AM-8:30 AM	Breakfast Business Meeting (Members Only) South Georgian Room - The Cloister
8:30 AM-12:00 NOON	Scientific Meeting - Ballroom Plantation Center
12:00 NOON-12:30 PM	Reception (Members, Spouses and Quests) Plantation Lounge
12:30 PM-1:30 PM	Lunch - The Cloister Restaurants
1:30 PM-5:00 PM	Scientific Meeting - Ballroom Plantation Center
6:15 PM-10:00 PM	Plantation Oyster Roast - (Trams begin leaving the Plan- tation Center 6:15 PM) Casual Dress.
Friday, November 7	
7:00 AM-8:30 AM	Breakfast Business Meeting (Members Only) South Georgian Room - The Cloister
8:30 AM-12:00 NOON	Scientific Meeting - Ballroom Plantation Center
12:00 NOON	Luncheon - The Cloister Restaurants
6:30 PM	Reception and Dinner - Plantation Lounge (Black Tie)
Saturday, November 8	
7:00 AM-8:30 AM	Breakfast - Cloister Dining Rooms
8:30 AM-12:00 NOON	Scientific Meeting - Ballroom Plantation Center

SEA ISLAND SENIORS PROGRAM

٠

à

•

į

Tuesday, November 4	
2:00 PM-5:00 PM	Registration Plantation Center
6:30 PM	Reception Dr. Frank Mayfield's Cottage #30
Wednesday, November 5	
8:30 AM	Breakfast Buffet - The Cloister South Georgian Dining Room
10:00 AM-11:30 AM	Nature Lecture and Jeep Ride. Jeeps leave from River- side (across from Plantation Center).
12:30 PM	Buffet Luncheon - South Georgian Dining Room

LADIES ACTIVITIES

Wednesday, November 5	
6:30 PM-8:00 PM	Plantation Lounge Reception
Thursday, November 6	
8:30 AM-5:00 PM	Ladies Hospitality - Cumberland Room Plantation Center
10:00 AM-12:00 NOON	Tour of Historical St. Simons. Buses leave from front of Riverhouse.
12:00 NOON-12:30 PM	Reception (Members, Spouses and Quests) Plantation Lounge
6:15 PM	Tram Makes First Run To Plantation Oyster Roast - Leaves from Plantation Center. (Casual Dress)
Friday, November 7	
10:00 AM-12:00 NOON	Shopping Trip to Galleries and Boutiques. Buses leave from Riverhouse.
11:00 AM-12:00 NOON	Tour of Cloister Kitchens (Limited) Meet in Main Lobby.
1:00 PM-5:00 PM	Qolf Tournament
2:00 PM-5:00 PM	Tennis Tournament
6:30 PM	Reception and Dinner Plantation Center (Black Tie)

Saturday, November 6

8:30 AM-12:00 NOON Ladies Hospitality - Cumberland Room Plantation Center

Note: All meals and part of Thursday and Friday dinners are included in the American Plan of dally room charges.

SCIENTIFIC PROGRAM

Thursday, November 6

SCIENTIFIC SESSION I MODERATOR: Thoralf M. Sundt, Jr., M.D.

8:30 WELCOME: Phanor L. Perot, M.D., Ph.D. - President

8:35

1. ENDOTHELIUM AND VASOSPASM

T. Bun, M.D., J. Peterson, Ph.D., *N. Zervas, M.D. Massachusetts General Hospital

The endothelium of cerebral arteries appears to lose its function following subarachnoid hemorrhage.

Dogs were subjected to two separate subarachnoid hemorrhages which caused severe basilar artery constriction within one week. The arteries were then studied angiographically and, after isolation in a "heart-lung device" which permitted: 1. simultaneous perfusion of the luminal surface at a chosen distending pressure and superfusion of the adventitial surface with the physiologic solutions; 2. electrophysiologic recording of intracellular smooth muscle membrane potenial; 3. biomechanical studies of contractility; and 4. scanning of electron microscopic examination of luminal and adventitial surfaces. The behavior of the vessel segments in vitro were examined with and without the endothelium.

The following observations were made:

1. Vasoconstriction induced in situ by subarachnoid blood is accompanied by a partial depolarization of the smooth muscle cell membrane potential.

2. Perfusion of the lumen with solutions containing serotonin or the endothelium-dependent vasodilator Substance-P result in *transient* constriction or prolonged vasodilation in normal control vessels, but *prolonged* constriction and transient vasodilatation in vessels chronically constricted in-situ.

3. Removal of the endothelium of normal vessels results in the same electrophysiological and biochemical properties seen in chronically constricted vessels.

It thus appears that the endothelium of vessels exposed to SAH becomes functionally inactivated, disrupting its ability to provide the media relaxing factors and to prevent the entry of vasoactive factors from blood. 8:55

2. IMPACT OF EARLY ANEURYSM SURGERY ON THE NATURAL HISTORY OF SUBARACHNOID HEMORRHAGE

*Douglas Chyatte, M.D., Thoralf M. Sundt, Jr., M.D., Nicolee C. Fode, R.N., M.S.

Yale University Medical Center

The management results for 195 patients admitted to our institution within 3 days of aneurysmal subarachnoid hemorrhage from the years 1979 to 1984 were analyzed with respect to the timing of surgical intervention. Twenty-six patients had no surgery, 53 patients were operated on within 0-3 days after hemorrage, 72 patients 4-9 days after hemorrhage, and 44 patients 10 or more days post hemorrhage. Overall, 53% of patients had an excellent outcome in follow up, 10% good outcome, 15% a poor outcome, and 24% died. Eighty-seven percent of patients who were Botterell Grade I on admission had an excellent result. Sixty percent of the Grade II patients had an excellent result while Grades III and IV patients had a less satisfactory outcome. the timing of surgical intervention did not affect management outcome in most instances, however, Grade II patients operated on within 10 days did somewhat better than those who were operated on later. the risk of rebleeding after hospital admission was relatively small and increased only modestly with time suggesting that a uniform policy of early surgery would have only a minor impact on the overall management results. Operative and postoperative complications were similar in all treatment groups suggesting that early surgery is safe and technically feasible.

Based on these observations, we recommend operating on "good" grade patients at the earliest convenient time and thus capitalizing on the small benefit of reduced rebleeding. Surgical intervention may be delayed in "poor" grade patients until their condition stabilizes.

9:15

۱

3. WHAT IS CEREBRAL VASOSPASM?

*N.F. Kassell, M.D., H. Joshita, M.D., R.M. Lehman, M.D., B.K.A. Weir, M.D., G.N. Nazar, M.D., T. Nakagomi, M.D., T. Sasaki, M.D. University of Virginia School of Medicine

It has yet to be determined whether vasospasm is caused by a thickening of the arterial wall or by vasocontraction. To elucidate the mechanism of the arterial narrowing, morphometric analyses of cerebral arteries evidencing vasospasm was conducted. Six cynomolfus monkeys has instillation of blood around middle cerebral artery, the contralateral side serving as control. Four groups of six rabbits each were also studied. The monkey's middle cerebral artery was reduced in diameter 55% anglographically and 60% morphometrically. In the rabbits, BaCl₂ narrowed the artery 50% morphometrically. Acute subarachnoid hemmorhage produced 45% morphometric narrowing. Chronic SAH produced 45% anglographic and 50% morphometric narrowing. The was no significant difference in the medial cross sectional area or percent of the media occupied by smooth muscle cells between the control and SAH sides in the monkeys or between the BaCl₂, acute and chronic SAH rabbit groups. Furthermore, there was no appreciable encroachment upon the lumen by intimal thickening in the monkeys or rabbits, although there were alterations in the endothelial morphology.

These data suggest that vasospasm is due to profound (normal or abnormal) contraction or failure of relaxation of smooth muscle cells and that is not produced by thickening of the arterial wall.

The following study was conducted to further characterize the arterial narrowing. A vasodilator "cocktail" consisting of adenosine, nitroprusside, and papaverine has been shown to produce maximal dilatation in a variety of vascular beds. **Control:** normal animals. **Control Plus Vasodilatation:** normal animals perfused with the cocktail prior to fixation. **Chronic SAH:** animals sacrificed 72 hours subsequent to intracisternal injection of 1cc/kg of blood. **Chronic SAH Plus Vasodilatation:** SAH plus perfusion with cocktail. **Vasoconstriction:** animals sacrificed 30 minutes subsequent to intracisternal injection of BaCl₂. **Vasoconstriction Plus Vasodilatation:** BaCl₂ animals perfused with cocktail. All animals were sacrificed by perfusion fixation. The vasodilation animals were perfused with the cocktail for 5 minutes prior to fixation.

The diameter of the basilar arteries in the **Control** and the **Control Plus Vasodilatation Groups** was not significantly different. BaCl₂ reduced the diameter 50% and SAH reduced the diameter 30%. There we no significant differences between the diameter of the **barium chloride plus vasodilatation group** and the **chronic SAH plus vasodilatation group** when compared to the **control** or the **control plus vasodilatation**. These data demonstrate that chronic vasospasm is fully reversible.

We conclude that experimentally produced cerebral vasospasm is a result of profound, but reversible, vasoconstriction. Caution must be exercised in extrapolating these results in experimental SAH to humans with ruptured aneurysms.

9:40 COFFEE BREAK

10:00

4. COMPLEX ANEURYSMS OF THE BASILAR ARTERY TREATED WITH CIRCULATORY ARREST, HYPOTHERMIA, AND BARBITUATE CEREBRAL PROTECTION

*Robert F. Spetzler, M.D., Mark N. Hadley, M.D. Barrow Neurological Institute

Complete circulatory arrest, deep hypothermia, and barbituate cerebral protection are efficacious surgical adjuncts in the treatment of giant intracranial aneurysms. We have used these techniques in the treatment of five patients with complex (1) or giant (4) basilar artery aneurysms with good results. The rationale, indications, and specific anesthetic and operative techniques will be reviewed. Our perioperative morbidity and long-term results support the use of these techniques in selected patients with complex intracranial vascular lesions.

10:20

5. RISK OF CAROTID ENDARTERECTOMY: AN ANALYSIS

[•]Donald O. Quest, M.D., J.W. Correll, M.D., J.P. Mohr, M.D., L. Lennihan, M.D., T.K. Tatemichi, M.D.

Columbia University, College of Physicians & Surgeons

A prospective analysis of 425 cartotid endarterectomies performed at the Neurological Institute of New York from 1983 to 1986 was carried out. Forty of the 425 operations were for asymptomatic disease - usually in patients with contralateral occlusion and severe stenosis on the asymptomatic side. 407 patients (95.8%) had no post-operative deficit. 18 patients developed a peri-operative stroke; 8 (1.9%) were minor deficits. 10 (2.4%) were major deficits. Four patients (.9%) had myocardial infarctions. Of the 10 patients with major deficits 7 had preexisting risks factors such as recent stroke, coronary artery disease, or other medical problems. 3 patients (0.7%) had only a prior TIA and not risk factors. In the current climate of heightened criticism of carotid emdarterectomy these figures demostrate that with a team of internists, neurologists, anesthesiologists, and neurosurgeons dedicated to evaluation and treatment of patients with cerebral vascular lisease ,low morbidity and mortality can be achieved, when comparing risk versus benefits for this surgical procedure it is important to consider the level of expertise of those treating the problem and the selection criteria for surgery. In addition the pre-operative condition of the patient must be considered when discussing post-operative complications.

10:40

6. MICROSURGICAL ANATOMY OF THE LENTICULOSTRIATE SYSTEM FROM THE MIDDLE CEREBRAL ARTERY TO ITS TERMINAL SUPPLY AND ITS SURGICAL RECONSTRUCTION

*James I. Ausman, M.D., Ph.D., Manuel Dujovny, M.D., Moises Vasques, M.D., Fernando G. Diaz, M.D., Ph.D., Ghaus Malik, M.D., Jose Selmon, M.D.

Henry Ford Hospital

The importance of the lenticulostriate arterial system in cerebral ischemia, intracerebral hemorrhage, AVM and aneurysm surgery requires a thorough understanding of its anatomy. 773 lenticulostriate arteries (LSA) or perforating branches (PFB's) from 29 unfixed human brains (58 hemispheres) were injected with polyester resin and studied. The following parameters were evaluated: outer diameter (OD), site of origin, branching patterns, length, and their pattern of distribution in the anterior perforated substance (APS).

12% (91 vessels) of the PFB's originated from A-1 through the short central artery (ShCA) and 9% (69 vessels) from the Recurrent Artery of Heubner (RAH) both forming the MEDIAL GROUP OF PFB's. 79% (613 vessels) of the PFB's originated from the Middle Cerebral Artery (MCA). Almost all of the PFB's formed the LATERAL and INTERMEDIATE GROUP of perforators. 42% of these PFB's formed the LATERAL QROUP, most of which arose as single arteries while the remainder came from common stems. In the INTERMEDIATE GROUP most (72%) of the PFB's arose from common stems.

An inverse relationship in the diameters of the RAH and ShCA was found to relate to the dominance of either in supplying the APS. The INTERMEDIATE QROUP was composed mostly by trunks which divided into small vessels before entering the APS in contrast to the LATERAL QROUP whose branches were of greater diameter and had fewer divisions. Regardless of the variations in the origins of the PFB's, the microanatomy of the vessel entry points into the APS was constant. The presence of intracerebral anastomoses between the different groups was very frequent (18 of 28 hemispheres), in contrast with the rare finding of extracerebral anastomoses (4 hemispheres).

In 28 hemispheres diluted silicone rubber was injected selectively through small catheters microsurgically located close to the three groups of PFB's. After 10 days of fixation 5mm horizontal brain slices were made and the distribution of the different groups of perforators was noted.

The thalamus did not receive irrigation from these vessels. Great differences were found between one brain and the other as well as between hemispheres of the same brain. These differences could explain the variability of the clinical picture produced by their occlusion.

Surgical reconstruction of the INTERMEDIATE AND LATERAL OROUPS of perforators was accomplished with microsurgical techniques and milliwatt laser anastomosis and will be presented included a direct approach to the ostium of the lenticulostriate arteries through the MCA trunk.

11:00

ł

7. MIDDLE CEREBRAL ARTERY ANEURYSMS -A 10 YEAR EXPERIENCE

*Eugene S. Flamm, M.D.

New York University School of Medicine

Aneurysms of the middle cerebral artery (MCA) comprises 20-25% of intracranial aneurysms in recently reported series. They pose several particular problems; these are reviewed in this paper which examines our experience with 140 MCA aneurysms operated upon in the past 10 years. These occured in 129 patients and represent 22.1% of 632 aneurysms operated upon during this period.

Of the 129 patients, 20 had bilateral MCA aneurysms that required separate craniotomies (15.5%); 13 of these patients had at least on additional aneurysm. Another 23 patients had a MCA aneurysm as one of multiple aneurysms (17.8%). Eight patients had 2 MCA aneurysms on the sme side (6.2%) in4 of these cases additional aneurysms were present. Although the incidence of bilateral MCA aneurysms is only 15.5%, the overall occurrence of multiple aneurysms including the MCA is 41.1% (53/129). This figure is considerably greater than the expected rate for multiple aneurysms.

Twenty-one patients had no SAH, 4 patients bled form an aneurysm other than the MCA, and 104 patients presented with SAH from the MCA aneurysm (80.6%). There were 4 deaths, all in Grade III and IV (Hunt) patients. There were 6 patients with significant postoperative neurological deficits. These 6 patients had complex MCA aneurysms, two of which had bled.

Particular problems that have been examined regarding MCA anuerysms include the management of complicated MCA aneurysms which may require the use of temporary occlusion of the MCA, suction decompression of the aneurysm prior to clipping, and EC/IC bypass. The increased use of CT scanning and more recently the use of digital intravenous angiography has led to more frequent diagnosis of aneurysms before hemorrhage has occured. These issues and the general surgical management of MCA aneurysms that has evolved with this experience will be presented.

11:20

8. SURGICAL RESULTS IN CHILDREN WITH MOYAMOYA DISEASE

Katsutoshi Kitamura, M.D., Masashi Fukui, M.D., Toshio Matsushima, M.D., Kanehiro Hasuo, M.D., Toru Kurokawa, M.D. Kyushu University, Fukuoka, Japan

Encephalo-duro-arterio-synangiosis (EDAS) was carried out on 21 sides of 15 children with Moyamoya disease. EDAS alone was done on 19 sides, and Encephalo-myo-synangiosis (EMS) was added later on two of them. EDAS and EMS were done together as one-stage operation on the remaining two sides of the 21.

Results: Nine out of 11 patients with transient ischemic attack (TIA) preoperatively showed a clinical improvement after surgery. Of the nine patients, the TIA disappeared immediately or within six months after surgery in seven, the TIA disappeared but involuntary movement remained in one, and the TIA disappeared in the upper limb but not in the lower limb in one. No improvement was achieved in two patients. Postoperative angiography was done on 17 sides of 12 patients to evaluate the surgical results. Development of new collaterals was observed markedly on 10 sides, and to a minor degree on three sides. When the development of the collaterals after EDAS was only little, EMS was added with a better subsequent formation of collaterals from the muscle in some cases. There were also cases in which EDAS and EMS were done at the same time and the collaterals developed only from the muscle. The data of the preand postoperative CT scan, EEG and PET scan will also be presented. As postoperative complications, temporary worsening of the TIA occurred in three cases, reversible ischemic neurologic deficit (RIND) in one and convulsive seizure in one.

Conclusion: The majority of the patients with a good development of collaterals after EDAS showed an improvement in the clinical symptoms. In some patients, however, the involuntary movement or TIA in the lower limb remained. In some of the cases with a poor result after EDAS, EMS could induce a better collateral circulation.

11:40

9. ASOCIATION OF ATRIAL NATRIURETIC PEPTIDE (ANP) WITH HYPOTENSION FOLLOWING EXPERIMENTAL BRAIN INJURY

*Michael J. Rosner, M.D., F.A.C.S., K.J. Chang, Ph.D., W.J. Qray, F.R.C.S., D. Esposito

University of North Carolina School of Medicine

Mechanical brain injury is associated with an intense sympathoadrenal discharge and immediate severe hypertension. This hypertension correlates closely with the release of circulating catecholamines for the first 500 seconds post-injury, but them hypostnsion, proportional to the degree of injury supervenes. This hypotension occurs when circulating epinephrine and norepinephrine are still elevated by orders of magnitude and does not represent sympathoadrenal collapse. Because artrial natriuretic peptide (ANP) is capable of reducing myocardial contractility and inducing hypotension, we tested the hypothesis that this hormone would be released as the result of mechanical brain injury.

In ten mongrel cats, weight 2.5-3.5 kg., underwent ventilation after methohexital induction of anesthesia and maintained using $N_2O:O_2$ (70:30) aand pancuronium bromide. After obtaining a stable baseline the fluid percussion injury was induced with the cat in the sphinx position. Arterial and venous blood samples were obtained. These paired samples were immediately placed in stop solution, spun down, the plasma separated and frozen in liquid nitrogen. ANP was assayed by radioimmunoassay technique.

At one hour after injury (3600 seconds) plasma ANP was very highly related to post-injury hypotension. A similar relationship was developing by 1000 seconds though it did not quite reach statistical significance.

These results are consistent with ANP acting as a myocardial depressant and vasodilator which may block and reverse the effects of hypercatecholaminemia. In extreme circumstances, massive release may lead to a cardiovascular rather than cerebral death of the animal. ANP is also a natriuretic agent and may be partly responsible for post-injury natriuresis and hyponatremia (mimicking SIADH).

12:00 LUNCH

1:30 ACADEMY AWARD PRESENTATION

2:45 PANEL DISCUSSION, ETHICS IN MARKETING AND QUALIFICATIONS

Moderator: Bennett M. Stein, M.D. Panel: W. Kemp Clark, M.D. David Kidder, Esq. Robert Q. Ojemann, M.D. Warren T. Reich, S.T.D. Frank R. Wrenn, M.D.

3:30 COFFEE BREAK

3:45 SENIORS AT SEA ISLAND Reminiscences

Friday, November 7

SCIENTIFIC SESSION II MODERATOR: Phanor L. Perot, M.D., Ph. D.

8:30

10. SINGLE NEURONAL ACTIVITY IN HUMAN TEMPORAL CORTEX RELATED TO LANGUAGE AND MEMORY

*George A. Ojemann, M.D., Otto D. Creutzfeldt, M.D., Ettore Lettiech, REEQ

University of Washington

Dominant hemisphere cortical resections under local anesthesia for the treatment of medically intractable epilepsy provide a unique opportunity to investigate single neuron activity related to language and memory. Changes in mean firing rates of extracellular neuronal activity recording during visual stimuli presented during measures of two language functions, naming and reading, were compared to recordings obtained during identical stimuli presented in a recent verbal memory measure, and in a control spatial matching measure. These recordings were obtained from left lateral temporal cortex just within the margin of the planned resection in 16 consenting patients. Satisfactory recordings were obtained in 12 patients, from 16 neuronal populations. Four populations showed no relation to language or memory; 8 populations demonstrated statistically significant increases in mean firing rates related to naming or reading, and 8 to recent verbal memory; half of each group were related to both. Several specific patterns of firing related to language and memory were identified, including several populations of neurons that increased firing with memory input and during word reading, and populations that fired briefly during naming or reading and in a more prolonged fashion when part of the recent memory measure. A particular pattern of firing related to recent memory was frequently observed: a relative prolonged

period of increased firing at the time of input of information to memory and again at its retrieval, with a relative reduction of firing during the time the memory was stored. These findings provide additional evidence of the participation of areas of lateral temporal cortex in language and recent verbal memory, and provide some of the first evidence on the nature of the neuronal activity that generates these functions.

8:50

11. THE CONTRIBUTION OF SPINAL MARGINAL NEURONS TO LATERAL THALAMIC NOCICEPTION

*Charles J. Hodge, Jr., M.D., A. Vania Apkarian, M.D., Steven Martini, M.D., Robert Martin, M.D.

State University of New York, Syracuse

Anatomic evidence using retrograde transport of horseradish peroxidase indicates that lamina I spinal neurons send their axons to the thalamus via the dorsolateral funiculus (DLF) ipsilateral to the thalamic termination site and contralateral to the lamina I cell body and the side of cutaneous innervation. This is of importance in understanding nociceptive mechanisms since the spinal lamina I thalamic projection is the major nociceptive specific input to the thalamus. The separation of the dorsolateral spinothalamic tract (DSTT) from the classical ventral spinothalamic tract (VSTT) allows experimental determination of the relative contributions of these two pathways to thalamic nociception, as described in this report.

Cats anesthetized with nitrous oxide and halothane were used for these experiments. Single unit recordings were made from the VPL and POm nuclei of the right snesory thalamus. Data was collected only from units responding to left hindlimb nociceptive stimulation (pinch or cutaneous thermal stimulation > 45 degrees C). A thoracic laminectomy was done and small cold probes used to reversibly block transmission through either the right ventrolateral quadrant, in which lies the VSTT, or the dorsolateral funiculus, in which lies the DSTT. Following determination of control thalamic nociceptive unit responses, the effects of separately blocking the DSTT and the VSTT were determined.

Recordings from 25 thalamic units were completed. The majority of the units were located in the shell region of VPL. Two units were located in POm. Only 2/25 units had their nociceptive responses decreased by blocking the VSTT. Nine of the 25 units demonstrated a dramatic decrease in nociceptive response during DSTT block.

These results indicate that lamina I input to the lateral thalamus is able to signal nociception, however not all nociceptive responses were dependent on this lamina I input. Clearly the DSTT, which is present in primates also, presents a paradox since anterolateral cordotomy, which spares this pathway, results in hypalgesia and pain relief. The persistence of the DSTT following cordotomy may be one of the reasons that there is, at times, return of pain and nociception after cordotomy. Furthermore, the simplistic notion of a single effective spinal cord nociceptive signaling system (labeled line concept) is not tenable in view of this data.

9:10

12. COMBINED INJURIES OF THE CLAVICLE AND BRACHIAL PLEXUS - MECHANISMS OF INJURY AND SURGICAL MANAGEMENT

*Suzie C. Tindall, M.D.

Emory University School of Medicine

Mechanisms of injury to the underlying brachial plexus in cases of clavicular fracture include: 1. progressive callus formation with compression of the plexus against the first rib, 2. direct injury to underlying neural elements by bone spicules or sharp fractured bone edges, and 3. associated stretch or traction injuries on plexus elements, particularly the axillary nerve. The mechanisms apply either singly or in combination. Appropriate patient workup includes clinical and plain film evaluation. CT scanning usually adds little useful information.

This presentation will emphasize the principles of surgical care that include: 1. drilling away the exuberant callus and removing any indriven bone spicules, 2. evaluation of injured elements using intraoperative nerve recording techniques, 3. primary or graft repair of injured elements if indicated and 4. repair of the clavicular fracture. If handled appropriately, these cases usually have a favorable outlook. Four representative cases from the author's surgical experience will be used to illustrate these mechanisms and surgical principles.

9:30

13. MULTIMODALITY EVOKED POTENTIALS IN COMATOSE PATIENTS

*R. Firshing, M.D., J. Luther, M.D., F.A. Boop, M.D., E. Eidelberg, M.D., J.L. Story, M.D., W.E. Brown, Jr. M.D.

The University of Texas, San Antonio

In 29 comatose patients (head injuries, intracerebral hemorrhages and other disorders) somatosensory short -(SER-S) and long (SER-L) latency, visual (VER), brain stem (BAER) and 40 Hz auditory (40 Hz AER) evoked responsed were investigated and correlated to coma grade and outcome.

Statistical evaluation showed that the best prognosticator of survival or non survival — not regarding the underlying cause of coma — is the combination of SER-S and age. Prognosis based on coma grade and age was less accurate. VER showed no correlation to outcome. The use of evoked potentials in comatose patients for assessment of prognosis and localization of the functional lesion is recommended.

9:50

14. ISOVOLEMIC HEMODILUTION IN EXPERIMENTAL FOCAL CEREBRAL ISCHEMIA

*R.C. Heros, M.D., Y-K Tu, M.D., D. Karacostas, M.D., N. Zervas, M.D., K. LeGree, M.D., A. Hyodo, M.D., G. Candia, M.D. Harvard Medical School

We have performed a study of **isovolemic** hemodilution (phlebotomy plus dextran infusion to bring the Het to about 30%) to see if cerebral protection can be achieved without the concomitant increase in blood volume, cardic work and intracranial pressure inherent to hypervolemic hemodilution.

Sixty dogs divided into a acute and a chronic group were used for the studies. The acute group of dogs havd multiple cerebral blood flow measurements by microspheres and the chronic group was kept alive for 1 week for detailed histologic examination and to ascertain whether hemodilution could be adequately maintained for at least 1 week after a single session of phlebotomy and dextran infusion. In all animals a variety of hemodynamic, cardiovascular, hematologic and rheologic parameters were measured. the ischemic insult consisted of a six hour period of occlusion of the right distal internal carotid and proximal middle cerebral arteries (twelve animals were sham operated-arterial manipulation but no occlusion).

Pertinent results can be summarized as follows:

1. Isovolemic hemodilution was of protective value in the model of experimental focal cerebral ischemia.

2. Such protection could be achieved without significant changes in blood volume, systemic arterial pressure, central venous pressure, pulmonary wedge pressure or cardiac index.

3. Isovolemic hemodilution did not result in an increase in ICP.

4. When compared with controls, hemodiluted animals experienced a significant increase in regional cerebral blood flow during the time of ischemia.

5. The cerebral protection and increased cerebral blood flow observed was most likely related to the reduction in viscosity consistently observed in the hemodiluted animals.

10:10 COFFEE BREAK

SCIENTIFIC SESSION III MODERATOR: William F. Collins, Jr., M.D.

10:25

15. HYPERFRACTIONATED RADIATION THERAPY FOR BRAINSTEM GLIOMA

*Michael S.B. Edwards, M.D

University of California San Francisco

Malignant gliomas involving the brainstem constitute 10-20% of pediatric brain tumors. While they can vary histologically from well-differentiated astrocytomas to glioblastoma multiforme, the majority are ultimately lethal regardless of histology. Controversy exists regarding therole of biopsy/resection in the management of these tumors. Radiation therapy mayu improve signs and symptoms in 75-90% of patients and has produced a 5 year survival in 20-30% of children. However, the vast majority of responses are under 18 months.

Because radiation is effective, albeit for a short period of time, we have undertaken the use of hyperfractionated radiation therapy as our primary treatment of brainstem gliomas. This technique allows the delivery of 25% more radiation to the tumor without an icrease in normal tissue toxicity.

Thirty children/adolescents (range 2-18 yrs.) have been treated since February of 1984. The diagnosis was confirmed by biopsy in 15 patients (12 mod. anaplastic, 2 highly anaplastic, 1 glioblastoma multiforme). The other 15 patients had clinical and radiographic evidence of brainstem tumor diffusely enlarging the brainstem (the majority were confirmed on MR scans). The median followup of these thirty patients is 55 weeks. Ten patients have died tumor related deaths (one died due to shunt infection at the time of tumor progression). All ten patients showed an initial improvement following radiation therapy which was confirmed by clinical and radiographic evaluation (CT and/or MRI), but recurred within 6 months of radiation therapy. These results are significantly better than any previous studies we have conducted or have been reported using conventional radiation with or without chemotherapy. Steriod dependence has been a significant problem and three episodes of oportunistic infections and sever myelosupression have been observed. The reason for the myelosupression is unclear.

The rationale for hyperfraction and the clinical and readiographic results will be reviewed. A longer follow-up period will be necessary to determine the long term effects of hyperfractionation on survival and its effect on normal tissue toxicity.

10:45

16. ALPHA-1-ANTITRYPSIN IN HUMAN BRAIN TUMORS

*Raymond Sawaya, M.D., Mario Zuccarello, M.D., Robert Highsmith, Ph.D.,

University of Cincinnati

Proteases and protease inhibitors play an important role in tumor biology. Their role in brain tumors is unknown because of lack of data. In this study, we have measured alpha-1-antitrypsin (A₁AT) and apha-2-macrogrobulin (A₂MQ) in 77 consecutive brain tumor extracts obtained freshly in the operating room. The results of these measurements were correlated with several clinical and laboratory parameter (age, Karnofsky, tumor size, PT, PTT, Fibrinogen, etc.), as well as with the content of the tissue in plaminogen activator (PA), a major proteolytic enzyme. A₁AT and A₂MQ were qualitatively assessed by ouchterlony immunodiffusion and PA was assayed electrophoretically on SDS gels. Appropriate controls were also included.

Sixty-eight percent of the samples were positive for A_1AT , while all specimens were negative A_2MG . The frequency of A_1AT positivity varied with the histological type and ranged from 100% for acoustic schwannoma to 50% for meningioma. Metastic tumors and glioblastoma were 91.6 and 78.9% positive respectively. Clinical and biological parameter failed to show statistically significant differences between the group of patients with positive A_1AT and the group with negative A_1AT with the exception of the following three parameters:

PA activity (P=0.001), **peritumoral brain edema** as quantitated on CT scan (P=0.05) and the preoperative **serum fibrinogen** level (P=0.025), all three values being higher in the group with positive A_1AT .

This study supports the hypothesis that A₁AT is produced locally by tumor cells in proportion to the regional proteolytic activity. To further support this hypothesis, we have immunohistochemically demonstrated A₁AT intracellularly in various brain tumors.

11:00

17. INTRACRANIAL GERM CELL TUMORS: PATHOLOGY AND TREATMENT

*Keiji Sano, M.D.

Teikyo University, Tokyo, Japan

If we admit the germ cell theory proposed by Friedman, Moore, Teilum and others, germinoma (seminoma), mature teratoma with malignant areas (teratocarcinoma), embryonal carcinoma, choriocarcinoma, endodermal sinus tumor, and socalled mixed germ cell tumors (tumors consisting of two or more of these tumor components, all belong to the category of germ cell tumors. We have experienced 93 cases of these tumors verified at surgery.

Among these tumors, 56 were pure types, such as mature teratoma or germinoma, and 37 were mixed tumors.

51 of these germ cell tumors were in the pineal region, 30 were in the suprasellar-hypothalamic region, and 12 were located in other sites. Cases of suspectred germinoma treated by radiation only were excluded from this series. Two-cell-pattern tumors of probable pineal parenchyma origin were also excluded. 72 of 93 cases were below the age of 20 years and 79 were males.

Pathological examinations include labelling index studies using bromouridine and its monoclonal antibody, and immunohistochemical studies. Germinoma showed unexpectedly high values of labelling index, which may explain its high radiosensitivity.

As for the treatment, three modalities of therapy should be recommended for three different tumor categories.

- 1. For germinoma, radiation or surgery followed by radiotherapy (we prefer the latter) should yield good results. In our series the 10-year survival rate by this modality of therapy was more than 85%.
- 2. Mature teratoma should be treated by surgical excision. In our series, the 10-year survival rate by total surgical removal was more than 78%.
- 3. The other kinds of germ cell tumors, namely, malignant teratoma, embryonal carcinoma, choriocarcinoma, endodermal sinus tumor, and mixed germ cell tumors usually show poor prognosis if treated by surgery and radiation only because of dissemination and hematogenous metastases. Combination chemotherapy with cisplatin, vinblastine and bleomycin (PVB therapy) seems to be promising for the treatment of these malignant tumors.

11:15

18. THERAPEUTIC EVALUATION OF A SPECIFIC ANTI-GLIOMA MONOCLONAL ANTIBODY (Mab) USING A SUBCUTANEOUS HUMAN GLIOMA XENOGRAFT MODEL

*Dennis E. Bullard, M.D., Yi Shing Lee, M.D., Ph.D., R. Edward Coleman, M.D., Darrell D. Bignar, M.D., Ph.D. Duke University Medical Center

The development of Mabs reactive with human tumorassociated antigens (TAA) provides a potential means of delivering therapeutic agents selectively to human malignant dliomas. To evaluate the therapeutic potential of 81C6, an IgQ, immunoglobulin, which defines a glioma extracellular matrix antigen, we radiolabeled and tested it in a subcutaneous athymic mouse xenograft model against D-54 MG, a human gliomaderived cell line (HGCL). In this well defined system, human tumors show progressive subcutaneous growth with a pattern of chemosensitivity roughly paralleling that seen in large human trials. D-54 MQ subcutaneous tumors were passaged in nude mice until they developed progressively growing 200-500 mm tumors. Animals were then injected via the tail vein with either buffer, unlabeled 81C6, 131-l radiolabeled 81C6, or 131-l radiolabeled 45.6, a nonspecific control Mab of the same isotype. Specific activities of the Mab range from 6.0-15.5 mCi/mg with protein doses from 7.6-167 up, the radiation doses delivered per animal for labeled 81C6 were 50, 250, 500, and 1000 uCi and 500 and 1000 uCi for 45.6. Tumors were measured thrice weekly until the individual tumor volume exceeded 5000 mm³. Tumor response was measured by growth delay, where the difference in days between the medians of the treatment and control groups to reach 1000 or 5000 mm³ was compared by the Wilcoxon Rank Sum test, and by comparing the number of tumors that had regression in volume after treatment using the Fisher Exact test. Statistically significant growth delays at 1000 mm³ were noted in 1/3 experiments with 500 uCl 81C6 (p=.000) and 2/3 for 1000 uCi 81C6 (p=.001..000). In none of the other groups was a statistically significant response noted. At 5000 mm³, statistically significant growth delays were seen with radiolabeled 81C6 in 1/1experiments at 250 uCi (p=.02), 4/4 at 500 uCi (p=.03-.000), and 2/2 at 1000 uCi (p=.001) and with 1/1 at 1000 uCi (p=.01). tumor regressors were noted in 0/39 animals treated with buffer and 0/20 with unlabeled 81C6; for radiolabeled 81C6, there were; 0/6 regressors at 50, 1/8 at 250, 7/39 at 500, and 15/28 at 1000 uCi. For radiolabeled 45.6, there were 0/10 regressors at 500 and 1/10 at 1000 uCi. Statically significant tumor regression was seen only at doses of 500 and 1000 uCi of 131-I-81C6. In this xenograft model, radiolabeled specific anti-glioma Mab

demonstrated therapeutic efficacy. The promising results obtained in this animal model suggested a potential value for this form of therapy against human malignant gliomas.

11:30 PRESIDENTIAL ADDRESS

Phanor L. Perot, M.D., Ph.D. Introduction - Griffith R. Harsh, III, M.D.

Saturday, November 8

SCIENTIFIC SESSION IV MALIGNANT BRAIN TUMORS, CURRENT CONCEPTS MODERATOR: M.S. Mahaley, Jr., M.D.

- 8:30 INNOVATIVE CURRENT THERAPIES FOR MALIGNANT GLIOMAS *M.S. Mahaley, Jr., M.D.
- 9:00 CHROMOSOME AMPLIFICATION AND OENCOGENES Sandra H. Bigner, M.D.
- 9:30 MONOCLONAL ANTIBODIES TO BRAIN TUMORS Darrell D. Bigner, M.D.
- 10:00 PHOTOCHEMOTHERAPY Stephen K. Powers, M.D.

10:30 COFFEE BREAK

- 10:45 REGIONAL ARTERIAL INFUSIONS John R. Kapps, M.D.
- 11:15 CHEMOTHERAPY OF CHILDHOOD TUMORS Henry Friedman, M.D.
- 11:45 INTERFERON AND ACTIVE IMMUNOTHERAPY M.S. Mahaley, Jr., M.D.

12:15 FINAL ANNOUNCEMENTS

12:30 ADJOURN

*Presenting Author

-NOTES ·

- .

-25-

RESIDENTS PAPER AWARD WINNERS

- WINNER -

MICHAEL G. NOSKO, M.D. UNIVERSITY OF ALBERTA

"The Effect of Clot Removal at 24 Hours on Chronic Vasospasms After Subarachnoid Hemorrhage in the Primate Model"

- RUNNER UP -

ERIC L. ZAGER, M.D. MASSACHUSETTS GENERAL HOSPITAL

"Reducing Cellular Energy Requirements: Screening for Agents That May Protect Against CNS Ischemia"

ACADEMY AWARD WINNERS

Paul M. Lin	
Hubert L. Rosomoff	
Byron C. Pevehouse	
Norman Hill	
Jack Stern	
Robert Ojemann	
Lowell E. Ford	
Charles H. Tator	
Earle E. Crandell	
Stephen Mahaley, Jr	
Chun Ching Kao	
John P. Kapp	
Yoshio Hosobuchi	
Gary G. Ferguson	
Richard L. Pressley	
David G. McLeone	
Arden F. Reynolds, Jr	
Richard L. Rapport	
Andrew G. Shetter	
John F. Howe	
Howard W. Blume	
Howard J. Senter	
Elisabeth M. Post	
David Dubuisson	
Dennis A. Turner	
Marc R. Mayberg	
David S. Baskin	
Kevin J. Kiwak	
Terry Lichtor	

THE AMERICAN ACADEMY OF NEUROLOGICAL SURGERY

GUESTS	QUESTS OF
Marshall B. Allen Augusta, Georgia	The Academy
Darell Bigner Durham, North Carolina	The Academy
Sandra Bigner Durham, North Carolina	The Academy
Luc Calliauw Brugge, Belgium	Edward R. Laws, Jr.
David A. Cavanaugh San Antonio, Texas	Jim L. Story
William R. Cheek Houston, Texas	E. Bruce Hendrick
Michael Edwards San Francisco, California	Charles B. Wilson
Raimund Firsching West Germany	Willis E. Browne, Jr.
Henry Friedman Durham, North Carolina	The Academy
Fred Qentili Toronto, Ontario, Canada	William M. Loughheed
Carl Oraf Sea Island, Georgia	The Academy

GUESTS

GUESTS OF

John Quarnaschelli Louisville, Kentucky	Theodore Kurze
Fleming Jolley Sea Island, Qeorgia	The Academy
Neal F. Kassell Charlottesville, Virginia	John A. Jane Charles G. Drake
James A. Kenning Philadelphia Pennsylvania	William A. Buchheit
J.M. McWhorter Winston-Salem, North Carolina	Eben Alexander, Jr.
Ghaus Malik Detroit, Michigan	James I. Ausman
Robert Martuza Boston Massachusetts	Nicholas T. Zervas
Ross Miller Hilton Head, South Carolina	The Academy
Stephen K. Powers Chapel Hill, North Carolina	The Academy
Donald O. Quest New York, New York	Clark Watts
Eugene Quindlen Mobile, Alabame	Lowell E. White, Jr.
Robert Ratcheson Cleveland, Ohio	Sidney Goldring

GUESTS

GUESTS OF

Morris W. Ray Memphis, Tennessee	Richard L. DeSaussure
Warren T. Reich Washington, D.C.	The Academy
Charles Rich Salt Lake City, Utah	Martin Weiss
Michael J. Rosner Chapel Hill, North Carolina	M.S. Mahaley, Jr.
George E. Roulhac Sea Island, Georgia	The Academy
Gerald Silverberg Stanford, California	John W. Hanberry
Robert F. Spetzler Phoenix, Arizona	John R. Green
Suzie C. Tindall Atlanta, Georgia	George T. Tindall
Rand Voohries New Orleans, Louisiana	Edward S. Connolly
Mao-Shan Wang Iowa City, Iowa	John C. VanQilder
Clarence B. Watridge Memphis, Tennessee	Donald F. Dohn
Allen R. Wyler Memphis, Tennessee	Arthur A. Ward, Jr.

PAST PRESIDENTS

PAST	VICE-PRESIDENTS	•
------	-----------------	---

Dean H. Echols	1938-39
Spence Braden	
Joseph P. Evans	
Francis Murphey	
Frank H. Mayfield	
A. Earl Walker	
Barnes Woodhall	
William S. Keith	
Howard A. Brown	
John Raaf	
E/Harry Botterell	
Wallace B. Hamby	
Henry Q. Schwartz	
J. Lawrence Pool	
Rupert B. Raney	
David L. Reeves	
Stuart N. Rowe	
Arthur R. Elvidge	
Jess D. Herrmann	
Edwin B. Boldrey	
George S. Baker	
C. Hunter Shelden	.1961-62
Samuel R. Snodgrass	
Theodore B. Rasmussen	
Edmund J. Morrissey	
George Maltby	
Guy L. Odom	
James G. Galbraith	
Robert H. Pudenz	.1969-70
William B. Scoville	
Robert L. McLaurin	
Lyle A. French	
Benjamin B. Whitcomb	
John R. Green	
William H. Feindel	
William H. Sweet	
Arthur A. Ward	
Robert B. King	
Eben Alexander, Jr.	
Joseph Ransohoff II	
Byron C. Pevehouse	
Sidney Goldring	
Russel H. Patterson, Jr	
Thomas Langfitt	

Francis Murphey1941
William S. Keith1942
John Raaf1943
Rupert B. Raney
Arthur R. Elvidge1946
John Raaf
Arthur R. Elvidge1948
F. Keith Bradford
David L. Reeves
Henry G. Schwartz
J. Lawrence Pool1952
Rupert B. Raney
David L. Reeves
Stuart N. Rowe
Jess D. Herrman
George S. Baker
Samuel R. Snodgrass
C. Hunter Shelden
Edmund Morrissey1960
Donald F. Coburn
Eben Alexander, Jr
George L. Maltby
Robert Pudenz
Francis A. Echlin
Benjamin Whitcomb
Homer S. Swanson
Augustus McCravey
Edward W. Davis
John R. Green
George J. Hayes
Richard L. DeSaussure
Ernest W. Mack
Frank E. Nulsen
Robert S. Knighton
Robert G. Fisher
H.T. Ballentine, Jr
George Ehni
Couruand H. Davis, Jr
John F. Mullan
Hugo Rizzoli
James W. Correll
E.B. Hendrick

PAST SECRETARY-TREASURER

Francis Murphey	1938-40
A. Earl Walker	1941-43
Theodore C. Erickson	1944-47
Wallace B. Hamby	
Theodore B. Rasmussen	

Eben Alexander, Jr.	1954-57
Robert L. McLaurin	1958-62
Edward W. Davis	1963-65
Robert G. Fisher	1966-68
Byron C. Pevehouse	1969-72

PAST SECRETARY

Byron C. Pevehouse	
Russel H. Patterson, Jr	1974-76
Phanor L. Perot, Jr.	1977-80
John T. Garner	1981-83

PAST TREASURER

Russel H. Patterson, Jr	
Phanor L. Perot, Jr.	1974-76
John T. Garner	1977-80
James T. Robertson	1981-83

· hit

PAST MEETINGS OF THE ACADEMY

Hotel Netherlands Plaza, Cincinnati, Ohio	October 28-29, 1938
Roosevelt Hotel, New Orleans, Louisiana	October 27-29, 1939
Tutor Arms Hotel, Cleveland, Ohio	October 21-22, 1940
Mark Hopkins Hotel, San Francisco and Amba	ssador Hotel
Los Angeles, California	November 11-15, 1941
The Palmer House, Chicago, Illinois	October 16-17, 1942
Hart Hotel, Battle Creek, Michigan	
Ashford General Hospital,	
White Sulphur Springs, West Virginia	September 7-9, 1944
The Homestead, Hot Springs, Virginia	September 9-11, 1946
Broadmoor Hotel, Colorado Springs, Colorado	October 9-11, 1947
Windwor Hotel, Montreal, Canada	September 20-28, 1948
Benson Hotel, Portland, Oregon	October 25-27, 1949
Mayo Clinic, Rochester, Minnesota	September 28-30, 1950
Shamrock Hotel, Houston, Texas	
Waldorf-Astoria Hotel, New York CitySepte	
Biltmore Hotel, Santa Barbara, California	October 12-14, 1953
Broadmoor Hotel, Colorado Springs, Colorado	October 21-23, 1954
The Homestead, Hot Springs, Virginia	October 27-29, 1955
Camelback Inn, Phoenix, Arizona	November 8-10, 1956
The Cloister, Sea Island, Georgia	November 11-13, 1957
The Royal York Hotel, Toronto, Canada	November 6-8, 1958
Del Monte Lodge, Pebble Beach, California	October 18-21, 1959
Copley Sheraton Plaza, Boston, Massachusett	sOctober 5-8, 1960
Royal Orleans, New Orleans, Lousiana	
El Mirador, Palm Springs, California	October 23-26, 1963
The Key Biscayne, Miami, Florida	November 11-14, 1964
Terrace Hilton Hotel, Cincinnati, Ohio	October 14-16, 1965
Fairmont Hotel & Towers,	
San Francisco, California	October 17-19, 1966
The Keybiscayne, Miami, Florida	November 8-11, 1967
Broadmoor Hotel, Colorado Springs, Colorad	0October 6-8, 1968
St. Regis Hotel, New York City	September 21, 1969
Camino Real Hotel, Mexico City	November 18-21, 1970
Sahara-Tahoe Hotel, Stateline, Nevada	September 26-29, 1971
New College, Oxford, England	September 4-7, 1972
Huntington-Sheraton Hotel,	
Pasadena, California	November 14-17, 1973
Southampton Princess Hotel,	
Southampton, Bermuda	
The Wigwam (Litchfield Park), Phoenix, Arizon	aNovember 5-8, 1975
The Mills Hyatt House,	
Charleston, South Carolina	November 10-13. 1976
Mauna Kea Beach Hotel, Kamuela, Hawaii	
Hotel Bayerishcer Hof, Munich Germany	
Hyatt Regency, Memphis, Tennessee	November 7-10, 1979
Waldorf Astoria, New York, New York	October 1-4, 1980

Sheraton Plaza, Palm Springs, California	November 1-4, 1981
Ritz-Carlton Hotel, Boston, Massachusetts	October 10-13, 1982
The Lodge at Pebble Beach, California	October 23-26, 1983
The Homestead, Hot Springs, Virginia	October 17-20, 1984
The Lincoln Hotel Post Oak, Houston, Texas	

1986

MEMBERSHIP LIST AMERICAN ACADEMY OF NEUROLOGICAL SURGERY Founded October, 1938

1

a

HONORARY MEMBERS	ELECTED
GUY LAZORTHES	1973
26 Rue D Auriol	
31 Toulouse, France	
VALENTINE LOQUE	1974
16 Rowan Road	
Hammersmith	
London W6 7DU	
U.K.	
QOSTA NORLEN	1973
Neurokirurgiska Kliniken	
Sahlgrenska Sjukhus	
Goteborg, SV Sweden	
KEIJI SANO	1975
Dept. of Neurosurgery	
School of Medicine	
University of Tokyo	
Tokyo, Japan	

SENIOR MEMBERS

ELECTED

EBEN ALEXANDER, JR.(BETTY) Bowman-Gray School of Medicine of Wake Forest University Winston-Salem, North Carolina 27103	1950
GEORGE S. BAKER (ENID) 607 North Litchfield Road P.O. Box 1234 Litchfield Park, Arizona 85340	1 940
H. THOMAS BALLANTRINE, JR. (ELIZABETH) Massachusetts General Hospital 15 Parkman Street - ACC 312 Boston, Massachusetts 02114	1951
EDWIN B. BOLDREY (HELEN) University of California Hospital 3rd Avenue and Parnassus San Francisco, California 94143	1 941
E. HARRY BOTTERELL (MARGARET) 2 Lakeshore Boulevard Kingston, Ontario, Canada K7M 4J6	1938
HOWARD A. BROWN 2841 Ptarmigan Dr., #1 Walnut Creek, California 94595	19 3 9
HARVEY CHENAULT (MARQARET) 2370 Nicholasville Road Lexington, Kentucky 40503	1938
QALE C. CLARK (MARION) University of California Medical Center San Francisco, California 94143	1970
DONALD F. COBURN (ELLIE) The Plaza 812 1303 Delaware Avenue Wilmington, Delaware 19806	1938
EDWARD W. DAVIS (BARBARA) 27831 Sweetbriar Road Troutdale, Oregon 97060	1 94 9
RICHARD DESAUSSURE (PHYLLIS) 920 Madison Avenue Memphis, Tennessee 38103	1 962

DONALD F. DOHN (CAROLYN) Singing River Neurosurgical Associates 3003 Short Cut Road Pascagoula, Mississippi 39567	1968
R.M. PEARDON DONAQHY (FRANCES) P.O. Box 5035 RDI - Hom of the Moon Road	1970
Montpelier, Vermont 05602	
CHARLES G. DRAKE (RUTH)	1958
University Hospital	
339 Windermere Road	
London, Ontario, Canada N6Q 2K3	
FRANCIS A. ECHLIN (LETITIA)	1944
P.O. Box 342	
New Paltz, New York 12561	
DEAN H. ECHOLS (FRAN)	Founder
Ochsner Clinic	
1514 Jefferson Highwy	
New Orleans, Louisiana 70121	
THEODORE C. ERICKSON (MARTHA)	1940
425 North Livingston Street	-010
Madison, Wisconsin 53703	
ROBERT FISHER (CONSTANCE)	1956
909 Park Avenue	
Plainfield, New Jersey 07060	
JOHN D. FRENCH (DOROTHY)	1951
The Center for the Health Sciences	
University of California	
Los Angeles, California 90024	
LYLE A. FRENCH (GENE)	1954
University of Minnesota	1001
Medical Center	
Minneapolis, Minnesota 55455	
JAMES Q. GALBRAITH (PEQQY)	1947
2515 Crest Road	
Birmingham, Alabama 35223	
PHILIP D. GORDY (SILVIA)	1968
1727 East Second Street	
Casper, Wyoming 82601	

ų

,

1

EVERETT G. GRANTHAM (MARY CARMEL) 234 East Gray Street Louisville, Kentucky 40202	1942
JOHN R. GREEN (GEORGIA) Barrow Neurological Institute 2910 No. 3rd Avenue Phoenix, Arizona 85013	1953
JAMES GREENWOOD, JR. (MARY) 1839 Kirby Avenue Houston, Texas 77019	1952
WALLACE B. HAMBY (ELEANOR) 2001 N.E. 47th Court Fort Lauderdale, Florida 33308	1938
JESS DRRMANN (MARY JO) Post Office Bos 135 Mountain Pine, Arkansas 71956	1948
WILLIAM S. KEITH (ELEANOR) 55 St. Leonards Crescent Toronto, Ontario, Canada M4N 3A7	Founder
ROBERT S. KNIGHTON (LOUISE) 9388 Avenida San Tinetto Cherry Valley, California 92223	1966
WILLIAM M. LOUGHEED (GRACE) Room 219, 7th Floor Toronto General Hospital 101 College Street Toronto, canada M5G 1L7	1962
HERBERT LOURIE (BETTY) 725 Irving Avenue, Suite 504 Syracuse, New York 13210	1965
JOHN J. LOWREY (CATHERINE "Katy") P.O. Box 4302 Kawaihae, Hawaii 96743	1965
GEORGE L. MALTBY (ISABELLA "Sim") 470 Black Point Road Scarsborough, Maine 04074	1942

FRANK MAYFIELD 506 Oak Street Cincinnati, Ohio 45219	Founder
AUGUSTUS McCRAVEY (HELEN) 1010 East Third Street Chattanooga, Tennessee 37403	1944
WILLIAM F. MEACHAM (ALICE) Vanderbilt University Hospital Division of Neurosurgery Nashville, Tennessee 37232	1952
EDMUND J. MORRISSEY (KATE) 2298 Pacific Avenue San Francisco, California 94115	1941
FRANCIS MURPHEY (MARGE) 3951 Quif Shores Road Apt. 1102 Naples, Florida 33940	Founder
GUY L. ODOM (MATALINE) 2812 Cheisea Circle Durham, North Carolina 27707	1946
J. LAWRENCE POOL (ANGELINE) Box 40 West Comwell, Connecticut 06796	1940
ROBERT W. PORTER (AUBREY DEAN) 6461 Bixby Hill Road Long Beach, California 90815	1962
ROBERT H. PUDENZ (RITA) 574 Qarfield Avenue South Pasadena, California 91030	1943
JOHN RAAF (LORENE) 1120 N.W. 20th Avenue, #100 Portland, Oregon 97209	Founder
AIDEN A. RANEY (MARY) 2010 Wilshire Blvd. Suite 203 Los Angeles, California 90057	1946

THEODORE B. RASMUSSEN (CATHERINE) 29 Surrey Drive Montreal, Quebec, Canada H3P 1B2	1947
HENRY Q. SCHWARTZ (REEDIE) Barnes Hospital Plaza Division of Neurological Surgery St. Louis, Missouri 63110	1942
C. HUNTER SHELDEN (ELIZABETH) 414 Fairmont Avenue Pasadena, California 91105	1 94 1
HOMER S. SWANSON (LaMYRA) 3649 Peachtree Rd., N.E. Unit 205 Atlanta, Georgia 30319	1949
WILLIAM H. SWEET (ELIZABETH) 309 Goddard Avenue Brookline, Massachusetts 02146	1950
JOHN TYTUS (VIRQINIA "Qina") Mason Clinic Seattle, Washington 98107	1967
ALFRED UIHLEIN (IONE) 200 First Street S.W. Rochester, Minnesota 55901	1950
A. EARL WALKER (AQNES) 1477 Wagontrain Drive, S.E. Albuquerque, New Mexico 87123	1938
EXUM WALKER (NELLE) 490 Peachtree Street, N.E. Atlanta, Qeorgia 30308	1938
BENJAMIN B. WHITCOMB (MARQARET) 50 Union Street Ellsworth, Maine 04605	1947

ELECTED **ACTIVE MEMBERS** JAMES I. AUSMAN (CAROLYN) 1978 Henry Ford Hospital 2799 West Grand Blvd. Detroit, Michigan 48202 **GILLES BERTRAND (LOUISE)** 1967 Montreal Neurological Institute 3801 University Street Montreal, Quebec, Canada H3A 1B4 ROBERT S. BOURKE (MARLENE) 1983 **Division of Neurosurgery** Albany Medical College Albany, New York 12208 JERALD S. BRODKEY (ARIELLE) 1977 24755 Chaorin Boulevard Suite #205 Beachwood, Ohio 44122 WILLIS E. BROWN, JR. (ANN) 1984 **Division of Neurosurgery** 7703 Floyd Curl Drive San Antonio, Texas 78284 DEREK A. BRUCE (FRANCES) 1984 34th - Civic Ctr. Blvd. **Division of Neurosurgery** Philadelphia, Pennsylvania 19014 WILLIAM A BUCHHEIT (LIN) 1980 3401 North Broad Street Philadelphia, Pennsylvania 19140 PAUL H. CHAPMAN (TANSY) 1983 Department of Neurosurgery Massachusetts General Hospital Boston. Massachusetts 02114 SHELLEY CHOU (JOLENE) 1974 University of Minnesota Medical Center Minneapolis, Minnesota 55455 W. KEMP CLARK (FERN) 1970 5323 Harry Hines Blvd. Dallas, Texas 75235

WILLIAM F. COLLINS, JR. (GWEN) Yale University School of Medicine 333 Cedar Street New Haven Connecticut 06510	1963
EDWARD S. CONNOLLY (ELISE) Ochsner Clinic 1514 Jefferson Highway New Orleans, Louisiana 70018	1973
JAMES W. CORRELL (CYNTHIA) 710 West 168th Street New York, 10034	1966
COURTLAND H. DAVIS, JR. (CARRIE) Bowman Gray School of Medicine Winston-Salem, North Carolina 27103	1967
STEWART B. DUNSKER (ELLEN) Mayfield Neurological Institute 506 Oak Street Cincinnati, Ohio 45219	1975
HOWARD M. EISENBERQ (JANET) The University of Texas Medical Branch Division of Neurosurgery Qalveston, Texas 77550	1985
WILLIAM H. FEINDEL (FAITH) Montreal Neurological Institute 3801 University Street Montreal, Quebec, Canada H3A 2B4	1959
EUGENE FLAMM (SUSAN) N.Y.U. Medical Center 550 First Avenue New York, New York 10016	1979
ELDON L. FOLTZ (CATHERINE) UCI Medical Center, Division of Neurosurgery 101 City Drive, S. Orange, California 92668	1960
RICHARD A.R. FRAZER (SARAH ANNE) 525 East 68th Street New York, New York 10021	1976
JOHN T. QARNER (CANDACE) 50 Allesandro Place Suite 400 Pasadena, California 91105 -42.	1971

HENRY GARRETSON (MARIANNA)	1973
Health Sciences Center	
316 MDR Bldg	
University of Louisville	
Louisville, Kentucky 40292	
	•
SIDNEY GOLDRING (LOIS)	1964
Barnes Hospital Plaza	
Division of Neurosurgery	
St. Louis, Missouri 63110	
ROBERT G. GROSSMAN (ELLIN)	1984
Baylor College of Medicine	
6501 Fannin, #A404	
Houston, Texas 77030	
ROBERT GRUBB (JULIA)	1985
Barnes Hospital Plaza	
St. Louis, Missouri 63110	
JOHN W. HANBERY (SHIRLEY)	1959
Division of Neurosurgery	
Stanford University Medical Center	
300 Pasteur Drive	
Stanford, California 94305	
	1090
GRIFFITH R. HARSH, III (CRAIG)	1980
University of Alabama Medical Center	
Birmingham, Alabama 35294	
MAJ. GEN. GEORGE S. HAYES (CATHERINE)	1962
MC USA	
303 Skyhill Road	
Alexandria, Virginia 22314	
MADE DETED HEIL ROLIN (DORVN)	1984
MARK PETER HEILBRUN (ROBYN)	1004
Division of Neurosurgery, #3B320 University of Utal Medical Center	
Salt Lake City, Utah 84132	
Sait Lake City, Otan 64152	
E. BRUCE HENDRICK (GLORIA)	1968
Hospital for Sick Children	
555 University Ave., Room 1502	
Toronto, Ontario, Canada M5Q 1X8	
ROBERTO C. HEROS (DEBBIE)	1985
Department of Neurosurgery	
Massachusetts General Hospital	
Boston, Massachusetts 02114	

CHARLES HODGE (LINDA) Department of Neurosurgery Upstate Medical Center Syracuse, New York 13210	1982
JULIAN HOFF (DIANNE) Department of Neurosurgery University of Michigan Ann Arbor, Michigan 48104	1975
HAROLD HOFFMAN (JO ANN) The Hospital for Sick Children Suite 1502, 555 University Avenue Toronto, Ontario, Canada M50 1X8	1982
EDGAR M. HOUSEPIAN (MARION) 710 West 168th Street New York, New York 10032	1976
ALAN R. HUDSON (SUSAN) St. Michael's Hospital 38 Shutter Street Toronto, Ontario Canada M5B 1A6	1978
WILLIAM E. HUNT (CHARLOTTE) Division of Neurological Surgery University Hospital 410 West 10th Avenue Columbus, Ohio 43210	1970
JOHN A JANE (NEOLLA) Department of Neurosurgery University of Virginia Charlottesville, Virginia 22901	1982
JOHN P. KAPP (LUREESE) Department of Neurosurgery University of Buffalo 50 High Street, #1202 Buffalo, New York 14203	1985
ELLIS B. KEENER (ANN) 915 East Lake Drive, NW Gainesville, Georgia 30506	1978

DAVID KELLY (SALLY) Bowamn Gray School of Medicine Winston-Salem, North Carolina 27103	1975
WILLIAM A. KELLY (JOAN) Department of Neurological Surgery RI-20 University of Washington Seattle,Washington 98195	1977
GLENN W. KINDT (CHARLOTTE) Division of Neurosurgery Box C-307 University of Colorado Medical Center 4200 East 9th Avenue Denver, Colorado 80262	1977
ROBERT B. KING (MOLLY) University Hospital Upstate Medical Center 750 East Adams Street Syracuse, New York 13210	1958
WOLFF M. KIRSCH (MARIE-CLAIRE) 531 Chamiso Lane, NW Albuquerque, New Mexico 87107	1971
DAVID G. KLINE Louisiana State University Medical Center 1542 Tulane Avenue New Orleans, Louisianna 70012	1972
RICHARD. S. KRAMER (ROBIN) Duke Hospital Durham, North Caroline 27710	1978
THEODORE KURZE 10 Congress Street Suite 340 Pasadena, California 91105	1967
THOMAS W. LANGFITT (CAROLYN) Hospital of University of Pennsylvania 34th and Spruce Streets Philadelphia, Pennsylvania 19104	1971

i

.

EDWARD R. LAWS, JR. (PEGGY) Mayo Clinic Rochester, Minnesota 55905	1983
RAEBURN C. LLEWELLYN (CARMEN) 5640 Read Boulevard Suite 840 New Orleans, Louisiana 70127	196 3
DONLIN M. LONG Department of Neurological Surgery John Hopkins Medical School Baltimore, Maryland 21205	1983
ALFRED J. LUSSENHOP Georgetown University Hospital Washington, D.C. 20007	1976
ERMEST W. MACK (BOBBIE) 505 South Arlington Avenue Suite 212 Reno, Neveda 89509	1956
M. STEPHEN MAHALEY, JR. (JANE) Division of Neurological Surgery 148 Clinical Sciences Bldg., U.N.C. Chapel Hill, North Carolina 27514	1972
LEONARD MALIS (RUTH) 1176 Fifth Avenue New York, New York 10029	1973
ROBERT L. MCLAURIN 111 Wellington Place Cincinnati, Ohio 45219	1955
JOHN F. MULLAN (VIVIAN) 7944 Stoney Isle Avenue Chicago, Illinois 60637	1963
BLAINE S. NASHOLD, JR. (IRENE) Duke University Medical Center Durham, North Carolina 27710	1967

FRANK E. NULSEN (GINNY) University Hospital of Cleveland 2074 Abington Road Cleveland, Ohio 44106	1956
GEORGE OJEMANN (LINDA) 6424 E. Mercer Way Mercer Island, Washington 98040	1975
ROBERT G. OJEMANN (JEAN) Neurosurgery Service Massachusetts General Hospital Boston, Massachusetts 02114	1968
BURTON ONOFRIO (JUDITH) Mayo Clinic Rochester, Minnesota 55901	1975
RUSSEL H. PATTERSON, JR. (JULIE) 525 East 68th Street New York, New York 10021	1971
S.J. PEERLESS (ANN) P.O. Box 5339 Terminal A University Hospital London, Ontario, Canada N6A 5A5	1977
PHANOR L. PEROT, JR. Department of Neurosurgery Medical University of South Carolina 171 Ashley Avenue Charleston, South Carolina 29425	1970
BYRON C. PEVEHOUSE (LUCY) 815 Eucalyptus Avenue Hillsborough, California 94010	1964
JOSEPH RANSOHOFF II (LORI ELLEN) New York University Medical Center 550 First Avenue New York, New York 10016	1965

ALBERT L. RHOTON, JR. (JOYCE) University of Florida, Box J265 Department of Neurosurgery Qainesville, Florida 32610	1984
HUGO RIZZOLI (HELEN) 2150 Pennsylvania Avenue, N.W. Washington, D.C. 20037	1973
THEODORE S. ROBERTS (JOAN) Madigan Army Med. Ctr. Neurosurgical Service P.O. Box 2511 Tacoma, Washington 98431-5439	1 97 6
JAMES T. ROBERTSON (VALERIA) Department of Neurosurgery University of Tennessee, Memphis 956 Court Avenue Memphis, Tennessee 38163	1971
FREDRICK A. SIMEONE 800 Spruce Street Philadelphia, Pennsylvania 19107	1981
JAMES C. SIMMONS (VANITA) 920 Madison Avenue Memphis, Tennessee 38103	1975
BENNETT M. STEIN 710 West 168th Street New York, New York 10032	1970
JIM L. STORY (JOANNE) 7703 Floyd Curl Drive San Antonio, Texas 78284	1972
THORALF M SUNDT, JR. (LOIS) 200 1st Street, S.W. Rochester, Minnesota 55901	1971
ANTHONY F. SUSEN (PHYLLIS) 3600 Forbes Avenue Pittsburgh, Pennsylvania 15213	1965

RONALD R. TASKER (MARY) Toronto General Hospital Room 7-221E 101 College Street Toronto, Ontario, Canada M5G 1L7	1971
JOHN TEW, JR. (SUSAN) 506 Oak Street Cincinnati, Ohio 45219	1973
GEORGE TINDALL (SUZIE) Emory University School of Medicine Division of Neurosurgery 1365 Clifton Road, N.E. Atlanta, Georgia 30322	1968
JOHN C. VAN GILDER (KERSTIN) University of Iowa Hospital Iowa City, Iowa 55242	1980
ARTHUR A. WARD, JR. (JANET) Department of Neurological Surgery RI-20 University of Washington Seattle, Washington 98195	1953
CLARK WATTS (PATTY) One Hospital Drive Ste. N522 Columbia, Missouri 65212	1975
BRYCE K.A. WEIR (MARY LOU) Univ. Alberta Clinical Sciences Bldg. Alberta, Canada T6G 2G3	1984
MARTIN H. WEISS (DEBBY) USC Medical Center 1200 N. State Street Los Angeles, California 90033	1981
W. KEASLEY WELCH (ELIZABETH) Children's Hospital Medical Center 300 Longwood Avenue Boston, Massachusetts 02115	1957

LOWELL. E. WHITE, JR. (MARGIE) University of Southern Alabama Division of Neuroscience Mobile, Alabama 36688	1971
ROBERT WILKINS (QLORIA)	1 973
Duke University Medical Center	
Third and Parnassus	
San Francisco, California 94143	
CHARLES B. WILSON	1966
Department of Neurological Surgery	
University of California Medical Center	
Third and Parnassus	
San Francisco, Californ 194143	
FRANK WRENN (BETTY)	1973
27 Memorial Medical Drive	
Greenville, South Carolina 29605	
DAVID YASHON (MYRNA)	1972
50 McNaughton Road	
Columbus, Ohio 43213	
NICHOLAS T. ZERVAS (THALIA)	1972
Massachusetts General Hospital	
Boston, Massachusetts 02114	

SENIOR CORRESPONDING MEMBERS

KARL AUGUST BUSHE Neurochirurgischen Klinik D-8700 Wurzburg Josef-Schneider-Strasse 11 West Germany	1972
SHOZO ISCHII Department Neurosurger Juntendo Medical College Tokyo, Japan	1975
KRISTIAN KRISTIANSEN (KARI) Oslo Kommune Uleval Sykehus Oslo, Norway	1962
WILLIAM LUYENDIJK Pr Bemhardlaan 60 Oegstgeest, The Netherlands	1973
KURT SHURMANN Director Neurochirurg Univ-Klinik Mainz Langenbeskstr 1	1978
6500 Mainz, West Germany	

- CO 11 E

CORRESPONDING MEMBERS

JEAN BRIHAY (MARTINE VAN GEERTRUYDEN) 1 Rue Heger-Bordet B-1000 Brussels, Belgium	1975
FERNANDO CABIESES Inst. Peruano De Formento Educativo Av. Arenales 371, of. 501 Apartado 5254 Lima Peru	1966
JUAN CARDENAS, C. Neurologo 4 Neurocirujano Av. Insurgentes Sur 594, Desp. 402 Mexico 12 D.F.	1966
JUAN C. CHRISTENSEN Ayacucho 2151 4 P Buenos Aires, Argentina	1970
GUISEPPE DALLE ORE (GIUSHI) Dipartimento Di Neurochirugia Ospedale Maggiore 371000 Verona, Italy	1970
HANS ERICH DIEMATH (KARIN) Hofrat Univ. Prof. Dr. Med. TraunstraBe 31 A5026 Salzburg, Austria	1970
HERMANN DIETZ Neurosurgical Clinic Hannover School of Medicine Hannover 3000-61 West Germany	1980
JOHN GILLINGHAM Royal Infirmary Laniston Place Edinburg, Scotland EH43 PB United Kingdom	1962
JAMIE G. GOMEZ (LUCY) Transversal 4 No. 42-00 Commutador 2-32 4070 Bogota 8, Columbia, South America	1975

SALVADOR GONZALEZ-COMEJO (ROSALIE) Av. Chapultepec Sur 130 Guadalajara, Mexico 44100	19 82
ERNEST H. GROTE (JULIA) Neurosurgery Department University Clinic 7400 Tubigen Federal Republic of Germany	1984
HAJIMI HANDA Director of Neurosurgery Kyoto University Hospital 54 Shogoin Kawahare, Sakyo-Ku Kyoto 606, Japan	1985
JOHN HANKINSON Department of Neurological Surgery Newcastle General Hospital Newcastle-Upon-Tyne 4 England	1973
HANS-PETER JENSEN (RETA) Neurochirurgische Universitatsklinik Kiel Weirmarer StraBe 8 D-2300 Kiel/West Germany	1980
RICHARD JOHNSON Department of Neurological Surgery Royal Infirmary Manchester, England	1974
KATSUTOSHI KITAMURA (YOSHIKO) University Kyushu Hospital Faculty of Medicine Maidashi, Fukuoka 812, Japan	1970
LAURI LAITINEN (KERSTIN) Department of Neurosurgery University Hospital S-901 85 Umea Sweden	1971

,

WILLIAM MARQUTH Director, Department of Neurochirurgischen Universitat Munchen Marchioninistrasse 15 8000 Munchen 70, West Germany	1978
RAUL MARINO, JR. Rua Maestro Cardim, 808 S. Paulo - SP Brazil 01323	1977
B. RAMAMURTHI (INDIRA) 2nd Main Road G.I.T. Colony Madras 4, India 600 004	1966
CHARAS SUWANWELA Chulalongkorn Hospital Medical School Bangkok, Thialand	1972
LINDSAY SYMON (PAULINE) The National Hospital, Queen Square London, WC1E 3BG, England	19 82
KJELD VAERNET (ANN) Department of Neurolsurgery Rigshospitalet 9 Blegdamsvej 2100 Copenhagen, Denmark	1970
SIDNEY WATKINS The London Hospital Whitechapel, London E 1 England	1975
GAZI YASARQIL Neurochirurgische Universitatsklinik Kantonsspital 8000 Zurich, Switzerland	1975

DECEASED MEMBERS

ATTENDED IN THE OWNER WATCH

DATE ELECTED

DR. SIXTO OBRADOR ALCALDE Madrid, Spain (Honorary)	4/27/67	
DR. JAMES R. ATKINSON Phoenix, Arizona (Active)	2/78	1970
DR. PERCIVAL BAILEY Evanston, Illinois (Honorary)	8/10/73	1960
DR. WILLIAM F. BESWICK Buffalo, New York (Active)	5/12/71	1959
DR. SPENCER BRADEN Cleveland, Ohio (Active)	7/20/69	Founder
DR. F. KEITH BRADFORD Houston, Texas (Active)	4/15/71	1938
DR. WINCHELL McK. CRAIG Rochester, Minesota (Honorary)	2/12/60	1942
DR. ARTHUR ELVIDGE Montreal, Quebec, Canada (Senior)	1/17/85	1939
DR. GEORGE EHNI (Senior)	9/2/86	1964
DR. JOSEPH P. EVANS Kensington, Maryland (Senior)	5/8/85	Founder
DR. WESLEY A. GUSTAFSON Jensen Beach, Florida (Senior)	7/16/75	1942

DR. HANNIBAL HAMLIN	6/28/82 6/28/8	1941
DR. HENRY L. HEYL (Senior)	3/10/75	1 95 1
DR. OLAN R. HYNDMAN Iowa City, Iowa (Senior)	6/23/66	1942
MR. KENNETH G. JAMIESON Brisbane, Australia (Corresponding)	1/28/76	1970
SIR GEOFFREY JEFFERSON Manchester, England (Honorary)	3/22/61	1951
HUGO KRAYENBUHL Zurich, Switzerland (Honorary)	1985	1974
DR. WALPOLE S. LEWIN Cambridge, England (Corresponding)	1/23/80	1973
DR. DONALD D. MATSON Boston, Massachusetts (Active)	5/10/69	1950
DR. KENNETH G. McKENZIE Toronto, Ontario, Canada (Honorary)	2/11/64	1960
DR. JAMES M. MEREDITH Richmond, Virginia (Active)	12/19/62	1946
DR. W. JASON MIXTER Woods Hole, Massachusetts (Honorary)	3/16/68	1951

DR. EDMUND J. MORRISSEY San Francisco, California (Senior)	2/8/86	1941
DR. HANS-WERNER PIA West Germany (Corresponding)	7/9/86	1978
DR. WILDER PENFIELD Montreal, Canada (Honorary)	4/5/76	1960
DR. HELMUT PENZHOLZ West Germany (Corresponding)	1985	1978
DR. RUPERT B. RANEY Los Angeles, California (Active)	11/28/59	1939
DR. R.C.L. ROBERTSON Houston, Texas (Senior)	2/85	1946
DR. STEWART N. ROWE Pittsburgh, Pennsylvania (Senior)	10/11/84	1938
DR. DAVID REYNOLDS Tampa, Florida (Active)	4/3/78	1964
DR. RICHARD C. SCHNEIDER Ann Arbor, Michigan (Senior)	6/9/86	1970
DR. WILLIAM B. SCOVILLE Hartford, Connecticut (Senior)	2/25/84	1944
DR. R. EUSTACE SEMMES Memphis, Tennessee (Honorary)	3/2/82	1955

DR. SAMUEL R. SNODGRASS Nashville, Indiana (Senior)	8/8/75	1939
DR. C. WILLIAM STEWART Montreal, Quebec, Canada (Corresponding)	1948	1948
DR. GLEN SPURLING LaJolla, California (Honorary)	2/7/68	1942
DR. HENDRIK SVIEN Rochester, Minnesota (Active)	6/29/72	1957
DR. THOMAS A. WEAVER, JR. Dayton, Ohio (Senior)	1985	1943
DR. BARNES WOODHALL Durham, North Carolina (Senior)	1985	1941

•



AMERICAN ACADEMY OF NEUROLOGICAL SURGERY 1986 ANNUAL MEETING EVALUATION

Please complete this evaluation from (omit those sessions or events you did not attend) and return to the Secretary, James T. Robertson, at your earliest convenience.

(1) Was the general context of the scientific program: C Excellent Poor (2) If you found it poor, was it because: □ Too much review of old knowledge? □ Too simple or elementary? □ Too complex or abstruse? □ Of little practical value? (3) Did the speakers aim their talks: 🗆 Too hiah □ Too low Just about right - SCIENTIFIC PROGRAM -Thursday's Excellent Poor Sessions Comments Excellent Fridavs D Poor Sessions Comments_ Saturdavs □ Excellent D Poor Sessions Comments

- SOCIAL PROGRAM -

What chang	ges would you like to see in future meetings?	
Changes of address):	of address and/or telephone (indicate office or home	
	t Name: James T. Robertson Department of Neurosurgery, UTCHS 956 Court Avenue Memphis, Tennessee 38163	

